Non-infectious pediatric uveitis: An update on immunomodulatory management

被引：21

作者：

Sharma S.M. ^{[1
]}

Dick A.D. ^{[2
]}

Ramanan A.V. ^{[3
]}

机构：

[1] Bristol Eye Hospital, Bristol BS1 2LX, Lower Maudlin Street

[2] Department of Clinical Sciences South Bristol, University of Bristol, Bristol

[3] Bristol Royal Hospital for Children, Royal National Hospital for Rheumatic Diseases, Bath

来源：

Pediatric Drugs | 2009年 / 11卷 / 4期

关键词：

Infliximab; Etanercept; Juvenile Idiopathic Arthritis; Uveitis; Adalimumab;

D O I：

10.2165/00148581-200911040-00002

中图分类号：

学科分类号：

摘要：

Pediatric non-infectious uveitis remains a rare but potentially sight-threatening group of diseases. However, early screening and treatment can improve outcomes. No single agent has proven to be efficacious in all cases. A wide variety of long-term immunomodulatory treatments are available; these agents differ in both their potency and side effect profiles. Corticosteroids remain an extremely valuable form of treatment in the short-term management of uveitis. Other major groups of immunomodulatory treatments include the calcineurin inhibitors and antimetabolites such as methotrexate, which is frequently used as the first-line agent. The biologics, including anti-tumor necrosis factor agents and interferons, are newer and potentially very useful therapies although side effects limit their use. Successful outcomes may be achieved with appropriate immunosuppressant therapy given early in the disease, although clinical trials are required to define the true efficacy of this strategy. © 2009 Adis Data Information BV. All rights reserved.

引用

页码：229 / 241

页数：12

共 120 条

[41]

Allali F., Benomar A., Karim A., Lazrak N., Mohcine Z., El Yahyaoui M., Chkili T., Hajjaj-Hassouni N., Behcet's disease in Moroccan children: A report of 12 cases, Scandinavian Journal of Rheumatology, 33, 5, pp. 362-363, (2004)

[42]

Baki Mudun A., Ergen A., Unal Ipcioglu S., Yarkin Burumcek E., Durlu Y., Okan Arslan M., Short-term chlorambucil for refractory uveitis in Behcet's disease, Ocular Immunology and Inflammation, 9, 4, pp. 219-229, (2001)

[43]

Rosenbaum J.T., Treatment of severe refractory uveitis with intravenous cyclophosphamide, Journal of Rheumatology, 21, 1, pp. 123-125, (1994)

[44]

Ardoin S.P., Kredich D., Rabinovich E., Schanberg L.E., Jaffe G.J., Infliximab to Treat Chronic Noninfectious Uveitis in Children: Retrospective Case Series with Long-term Follow-up, American Journal of Ophthalmology, 144, 6, (2007)

[45]

Foeldvari I., Nielsen S., Kummerle-Deschner J., Espada G., Horneff G., Bica B., Olivieri A.N., Wierk A., Saurenmann R.K., Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: Results of a multinational survey, Journal of Rheumatology, 34, 5, pp. 1146-1150, (2007)

[46]

Gallagher M., Quinones K., Cervantes-Castaneda R.A., Yilmaz T., Foster C.S., Biological response modifier therapy for refractory childhood uveitis, British Journal of Ophthalmology, 91, 10, pp. 1341-1344, (2007)

[47]

Saurenmann R.K., Levin A.V., Rose J.B., Parker S., Rabinovitch T., Tyrrell P.N., Feldman B.M., Laxer R.M., Schneider R., Silverman E.D., Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis, Rheumatology, 45, 8, pp. 982-989, (2006)

[48]

Kahn P., Weiss M., Imundo L.F., Et al., Favorable response to high-dose infliximab for refractory childhood uveitis, Ophthalmology, 113, pp. 860-864, (2006)

[49]

Biester S., Deuter C., Michels H., Et al., Adalimumab in the therapy of uveitis in childhood, Br J Ophthalmol, 91, pp. 319-324, (2007)

[50]

Vazquez-Cobian L.B., Flynn T., Lehman T.J., Adalimumab therapy for childhood uveitis, J Pediatr, 149, pp. 572-575, (2006)

← 1 2 3 4 5 6 7 8 9 10 →